SCHEMBL18220237

SCHEMBL18220237

CCC(O)CNS(=O)(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(N4CCN(C)CC4)ccc3c2)o1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.36
CTSK P43235 6/20 0.34
CTSB P07858 5/20 0.34
HPGD P15428 3/20 0.34
LMNA P02545 1/20 0.34
KCNH2 Q12809 1/20 0.34
CTSS P25774 4/20 0.33
PRKD1 Q15139 3/20 0.33
TP53 P04637 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
ALDH1A1 P00352 3/20 0.33
MAPT P10636 2/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
HTR3A P46098 1/20 0.33
ABL1 P00519 1/20 0.33
KDM4E B2RXH2 2/20 0.32
GAA P10253 2/20 0.32
CTSL P07711 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17120871 0.94 APP (0.36) APPCTSKCTSBHPGDLMNA
SCHEMBL18220251 0.93 APP (0.35) APPHPGDLMNATP53RXFP1
SCHEMBL18220242 0.92 HPGD (0.40) APPCTSKCTSBHPGDLMNA
SCHEMBL18221405 0.85 ALDH1A1 (0.35) APPHPGDLMNATP53ALDH1A1
SCHEMBL24076143 0.85 MAPT (0.44) APPHPGDLMNATP53ALDH1A1
SCHEMBL18220129 0.85 APP (0.47) APPHPGDLMNAPRKD1RXFP1
SCHEMBL17120870 0.85 ALDH1A1 (0.38) APPCTSKCTSBHPGDLMNA
SCHEMBL18220253 0.84 LMNA (0.43) APPHPGDLMNATP53RXFP1
SCHEMBL18219914 0.84 APP (0.48) APPCTSKCTSBCTSSALDH1A1
SCHEMBL23134343 0.84 APP (0.40) APPHPGDLMNAKCNH2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885CTSK 1830/4885CTSB 1386/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885CTSK 1830/4885CTSB 1386/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885CTSK 1825/4885CTSB 1362/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885CTSK 1825/4885CTSB 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.